Sacituzumab Govitecan for Triple-Negative Breast Cancer: Aditya Bardia, MD

Recently, the FDA granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics, Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease. The FDA had previously granted accelerated approval to sacituzumab govitecan based on the results of the phase 1/2 IMMU-132-01 study (NCT01631552); the phase 3 ASCENT study (NCT02574455)...
Continue reading

Sacituzumab Govitecan Granted Regular Approval for Triple-Negative Breast Cancer

The FDA has granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who previously have been treated with two or more systemic therapies, at least one of them for metastatic disease. Previously, the FDA had granted accelerated approval to sacituzumab govitecan based on the results of the phase 1/2 IMMU-132-01 study (NCT01631552); the ASCENT study (NCT0257445...
Continue reading

FDA Grants Approval to Sacituzumab Govitecan-Hziy for TNBC

Accelerated approval was granted to sacituzumab govitecan-hziy (Trodelvy™, Immunomedics, Inc), a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, for patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies. Sacituzumab govitecan-hziy works by targeting the Trop-2 receptor, mitigating cancer growth and spread. In addition, this drug is linked to topoisomerase inhibitor, which is a chemical compound toxic to cancer cells. "Me...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.